Pre-clinical studies attest the potential of Hsp90 inhibition in inducing tumor growth inhibition, in reducing metastatic potential, and in sensibilizing tumors to the effect of other therapies, possibly as a consequence of the inhibition of DSBs repair and cell cycle checkpoint activation [23,33,35,53,54,55,56,57,58,59]. This evidence concerns the gene HSP90AA1 and neoplasm.